| Rheumatoid Arthritis
Cyltezo vs Olumiant
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Cyltezo vs Olumiant with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOlumiant has a higher rate of injection site reactions vs Cyltezo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Olumiant but not Cyltezo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyltezo
Olumiant
At A Glance
SC injection
Every other week
TNF-alpha inhibitor
Oral
Once daily
JAK inhibitor
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Panuveitis
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg every other week SC; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Crohn Disease, Ulcerative Colitis 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week SC starting Day 29.
Psoriasis vulgaris, Panuveitis 80 mg initial dose, then 40 mg every other week SC starting 1 week after initial dose.
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, accidental injury, nausea, urinary tract infection, flu syndrome, abdominal pain, hyperlipidemia, back pain, hypertension, hematuria
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, acute liver failure, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Pharmacology
Adalimumab-adbm is a TNF-alpha antagonist that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, modulating inflammatory responses and reducing concentrations of acute phase reactants such as CRP and ESR.
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyltezo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Cyltezo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Cyltezo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyltezo.
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyltezoView full Cyltezo profile
OlumiantView full Olumiant profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.